Hepatocellular carcinoma (HCC) is a major public health concern that is promoted by
obesity and associated liver complications. Onset and progression of HCC in obesity is a …

Non-alcoholic fatty liver disease (NAFLD) is a burgeoning global public health distress, with
an estimated 25% of the world population affected. Despite the increasing prevalence and …

Resmetirom, a liver-directed, orally active agonist of THR-β, could play a favorable role in
treating NASH, but little is known about the underlying mechanism. A NASH cell model was …

BACKGROUND Nonalcoholic fatty liver disease (NAFLD) is a clinicopathological entity
characterized by intrahepatic ectopic steatosis. As a consequence of increased consumption …

Altered metabolic function has many detrimental effects on the body that can manifest as
cardiovascular and liver diseases. Traditional approaches to understanding and treating …

This study examined the preventative effects of esculeogenin A (ESGA), a newly discovered
glycan from tomato, on liver damage and hepatic steatosis in high-fat-diet (HFD)-fed male …

Backgrounds Non-alcoholic fatty liver disease (NAFLD) is a common condition affecting>
25% of the population worldwide. This disorder ranges in severity from simple steatosis (fat …

Background To comprehend the influences of fenofibrate on hepatic lipid accumulation and
mitochondrial function-related signaling pathways in mice with non-alcoholic fatty liver …

Objective Non-alcoholic steatohepatitis (NASH) has become a global medical problem.
Currently, there is no approved pharmacologic treatment for this condition. Previous studies …

Non-alcoholic fatty liver disease (NAFLD) is a chronic liver disease, with its incidence
increasing in parallel with the global prevalence of obesity and type 2 diabetes mellitus …